Shares of BioSante Pharmaceuticals (BPAX) are plunging today after the company said two phase III studies of it LibiGel testosterone treatment, designed to boost female libido, did not meet primary endpoints.
The treatment did not differ significantly from a placebo in terms of the either the number of satisfying sexual events or sexual desire.
BioSante said it will continue to analyze the study data.
The drug would have been the first of its kind designed to enhance female sexual function. Media have called the treatment the female version of Pfizer's (NYSE:PFE) Viagra or Eli Lilly's (NYSE:LLY) Cialis, although the drugs work differently.
BioSante shares are falling today, as are shares of Antares Pharma (AIS), which is entitled to receive royalty payments on LibiGel.
Any ideas and opinions presented in all Market News Video clips are for informational and educational purposes
only, and do not reflect the opinions of BNK Invest, Inc. or any of its affiliates, subsidiaries or partners.
In no way should any content contained herein be interpreted to represent trading or investment advice.
None of the information contained herein constitutes a recommendation that any particular security, portfolio,
transaction, or investment strategy is suitable for any specific person. All viewers agree that under no
circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held
liable for any loss or damage caused by your reliance on information obtained. Read Full Disclaimer.